Tekla Life Sciences Investors Cash Flow Conversion Efficiency
Tekla Life Sciences Investors cash flow conversion efficiency. Based on the latest financial reports, Tekla Life Sciences Investors (HQL) has a cash flow conversion efficiency ratio of -0.002x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.22 Million) by net assets ($560.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tekla Life Sciences Investors (1996–2025)
Cash flow conversion efficiency of Tekla Life Sciences Investors from 1996 to 2025. This chart illustrates how Tekla Life Sciences Investors's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Tekla Life Sciences Investors stock price today for real-time trading data and today's change.
Tekla Life Sciences Investors Cash Flow Conversion Ratio Explained
Tekla Life Sciences Investors cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tekla Life Sciences Investors Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tekla Life Sciences Investors ranked by their cash flow conversion efficiency. Also see HQL market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Abacus Group
AU:ABG
|
0.030x |
|
Turaco Gold Ltd
AU:TCG
|
-0.196x |
|
Vibhavadi Medical Center Public Company Limited
BK:VIBHA
|
0.043x |
|
Laurent-Perrier
PA:LPE
|
0.002x |
|
Jinneng Science&Tech Co Ltd
SHG:603113
|
-0.049x |
|
Founders Metals Inc.
V:FDR
|
-0.006x |
|
ANGLO ASIAN MINING
F:A4A
|
N/A |
|
AmRest Holdings SE
MC:EAT
|
0.278x |
Annual Cash Flow Conversion Efficiency for Tekla Life Sciences Investors (1996–2025)
The table below shows the annual cash flow conversion efficiency of Tekla Life Sciences Investors from 1996 to 2025. Review Tekla Life Sciences Investors (HQL) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $513.66 Million | $-2.32 Million | -0.005x | -319524554.28% |
| 2021-09-30 | $523.44 Million | $-0.74 | 0.000x | +12.40% |
| 2019-09-30 | $384.16 Million | $-0.62 | 0.000x | +100.00% |
| 2014-09-30 | $444.09 Million | $-52.57K | 0.000x | -477.75% |
| 2013-09-30 | $302.29 Million | $9.47K | 0.000x | -99.97% |
| 2012-09-30 | $227.08 Million | $21.11 Million | 0.093x | -86.60% |
| 2011-09-30 | $170.60 Million | $118.30 Million | 0.693x | +9075.24% |
| 2010-09-30 | $251.40 Million | $1.90 Million | 0.008x | -85.55% |
| 2009-09-30 | $248.60 Million | $13.00 Million | 0.052x | +23.11% |
| 2008-09-30 | $277.80 Million | $11.80 Million | 0.042x | +453.59% |
| 2007-09-30 | $308.00 Million | $-3.70 Million | -0.012x | -53.37% |
| 2006-09-30 | $268.10 Million | $-2.10 Million | -0.008x | +43.87% |
| 2005-09-30 | $229.30 Million | $-3.20 Million | -0.014x | +16.35% |
| 2004-09-30 | $191.80 Million | $-3.20 Million | -0.017x | -32.36% |
| 2003-09-30 | $190.40 Million | $-2.40 Million | -0.013x | +23.59% |
| 2002-09-30 | $157.60 Million | $-2.60 Million | -0.016x | -86.77% |
| 2001-09-30 | $215.10 Million | $-1.90 Million | -0.009x | +48.04% |
| 1998-09-30 | $100.00 Million | $-1.70 Million | -0.017x | -49.60% |
| 1997-09-30 | $132.00 Million | $-1.50 Million | -0.011x | +6.74% |
| 1996-09-30 | $123.10 Million | $-1.50 Million | -0.012x | -- |
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more